Skip to main content

Magenta Elevate™ EFS in High-Risk PCI Patients

Completed · Not applicable · NCT05727059

Conditions: High-risk Percutaneous Coronary Intervention

At a glance

Research payments reported, 2025
$261,791
U.S. investigators named
10
Sites paid
10
Planned or actual enrollment
18

About the trial

Sponsor
Magenta Medical Ltd.
Tested
The Elevate™ System (device)
Dates
Started 2023-05-08; completion 2024-01-02
Results posted
Not yet

The Elevate™ EFS study is designed to evaluate the safety and feasibility of the Magenta Elevate™ percutaneous Left Ventricular Assist Device (pLVAD) System in patients undergoing non-emergent, high-risk percutaneous coronary interventions.

From ClinicalTrials.gov, last updated 2024-09-26. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Magenta Medical Inc reported $261,791 in research payments for this study in 2025 (14 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.